REG - Creo Medical Group - Director/PDMR Shareholding

Creo MedicalAnnouncement

16/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241216:nRSP1953Qa&default-theme=true

RNS Number : 1953Q  Creo Medical Group PLC  16 December 2024

 

LEI: 213800H188ZDCWWXFA21

Creo Medical Group plc

("Creo" or the "Company")

 

Director/PDMR Share Dealings

 

The Company has been informed that on 13 December 2024 Kevin T. Crofton,
Non-Executive Chairman, purchased Ordinary Shares in the Company at an average
price of 17.015 pence per share as follows:

 

 Director/PDMR Name  No. of Ordinary Shares Acquired  Resultant Shareholding post transaction  % of voting rights post transaction
 Kevin T. Crofton    1,179,000                        4,745,666                                1.15%

 

This announcement contains inside information.

 

For further information please contact:

 

 Creo Medical Group plc                                                  www.creomedical.com (http://www.creomedical.com/)
 Richard Craven, Company Secretary                                       Via Walbrook PR

 Cavendish Capital Markets Limited

 (Nominated Adviser and Joint Broker)                                    +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume / George Lawson (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                                           +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 William Baunton (ECM)

 Walbrook PR Ltd                Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 Philip Marriage                Mob: +44 (0)7867 984 082

 

 

 

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Kevin T. Crofton

 2   Reason for the notification
 a)  Position/status                                              Non-Executive Chairman

 b)  Initial notification/Amendment                               Initial Notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Creo Medical Group plc

 b)  LEI                                                          213800H188ZDCWWXFA21

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

     Identification code                                          GB00BZ1BLL44

 b)  Nature of the transaction                                    Purchase of Ordinary Shares

 c)  Price(s) and volumes(s)                                      Price(s)                     Volume(s)
     Average price of £0.17015                                                                 1,179,000

 d)  Aggregated information

     Aggregated volume                                            1.179,000

     Price                                                        Average price of £0.17015

 e)  Date of the transaction                                      13 December 2024

 f)  Place of the transaction                                     London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFFELFVLELIS